The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia

Authors:

Abstract
No abstract available
Funding Information
  • Japan Agency for Medical Research and Development (JP22kk0305014)

This publication has 16 references indexed in Scilit: